- Home
- MKTW vs ATRA Comparison
MKTW vs ATRA Comparison
Compare MKTW & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MKTW | ATRA |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1M | 37.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MKTW | ATRA |
|---|---|---|
| Price | $14.50 | $4.36 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $20.00 | $6.00 |
| AVG Volume (30 Days) | 12.1K | ★ 197.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.45% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.75 | ★ $2.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.08 | $4.20 |
| 52 Week High | $21.74 | $19.15 |
Technical Indicators
Market Signals| Indicator | MKTW | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 37.80 | 28.57 |
| Support Level | $13.92 | $4.37 |
| Resistance Level | $15.79 | $5.11 |
| Average True Range (ATR) | 0.65 | 0.34 |
| MACD | -0.19 | 0.32 |
| Stochastic Oscillator | 19.05 | 1.11 |
Price Performance
Historical ComparisonAbout MKTW MarketWise Inc.
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).